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Abstract: Probiotic milk has been previously demonstrated to reduce the number of respiratory
infections (RI) among children attending day care centres. Thus, this pilot study was aimed to
assess the efficacy and the safety of 3 month treatment with Bacillus clausii in the prevention
of recurrent respiratory infections (RRI) in children. Eighty children with RRI were studied:
40 of them were randomly treated with B. clausii for 3 months, and followed up for further 3
months; 40 were included in the control group during the same period. Children treated with
B. clausii had shorter duration of RI in comparison with the control group both during the
treatment phase (mean 11.7 days vs 14.37; p=0.037) and the follow-up period (mean 6.6 days
vs 10.92; p=0.049). This effect was evident also in allergic children during the follow-up. In
conclusion, this pilot study provides the first preliminary evidence that B. clausii may exert a
significant and persistent impact on RI in children and is safe and well tolerated.
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Introduction
Respiratory infections (RI), mainly involving the upper airways, are common in
children and their recurrence constitutes a demanding challenge for the paediatrician
(BWHO 1998). It has been proposed that to diagnose recurrent RI (RRI) at least one
of the following criteria has to be present: 1) >6 RI per annum, 2) >1 RI per month
involving the upper airways from September to April, 3) >3 RI per annum involving
the lower airways (Gruppo di Studio di Immunologia della società Italiana di Pediatria
1988). Moreover, RRI represent a social problem both concerning economic aspects
and the influence on the family and social milieu of the child. In addition, allergic
children have more frequent and severe respiratory infections than nonallergic children
(Ciprandi et al 2006). In recent years, following the increase in the incidence of
antibiotic resistance, interest in preventive treatment has intensified. Such treatment
should contribute to the prevention of RRI, thus reducing the usage and excessive
consumption of antibiotics. Furthermore, it has been established that the intestinal
microflora plays an important role in the maturation of the immune system (Holt et
al 1997).
Probiotics are vital bacteria that colonize the intestine and modify its microflora
with benefits for the host. They are present in foodstuffs such as yogurt and other
dairy products. To exert their beneficial effects, probiotics must be able to overcome
the obstacle of gastric acidity, to proliferate and to colonize the intestine even in the
presence of biliary acids and of drugs such as antibiotics. They must adhere to intestinal
walls, reducing their permeability and potentiate the local immune response, especially
through secretory immunoglobulin (Ig) A (Isolauri et al 2001).
Probiotics are not pathogens as they are not virulent and consequently, their intake
is usually not associated with undesirable effects.
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The beneficial effect of probiotics is also to be ascribed
to its capacity to modulate the immune response. The
immune response dependent on Th1 lymphocytes (Th1)
deputy to defend from viruses and bacteria is not fully
efficient because it has not completely matured. Whereas,
the Th2 response to antigens prevails and is often enhanced
due to contact with environmental allergens, resulting in
early activation of allergic responses (type I IgE-mediated
allergic responses). Probiotics are able to induce an antigenic
stimulation that leads to release of interleukin (IL) 12 by
antigen-presenting cells (APC), which promotes the
maturation of the immune system and the Th1 response.
Furthermore, they reduce the production of IL4, which
specifically regulates the development of the Th2 phenotype
and leads to an increase in the synthesis of IgE, eosinophilia
and atopic disease. Probiotics have anti-inflammatory
properties related to the stimulation of secretory IgA
synthesis in mucous membranes and the production of
cytokines (Hattakka et al 2001). They also stimulate the
synthesis of interferon-gamma (IFN-γ) and have
antimicrobial activity as a result of the production of lactic
acid, H2O2 and natural antibiotic substances with potent
antiviral and antibacterial activity.
It has been previously reported that the prophylactic use
of a probiotic milk reduced the number and the severity of
RI among children attending day care centres (Hattakka et
al 2001). Probiotics are microorganisms that exhibit a
beneficial effect on the health of the host (Kaur et al 2002)
and the interaction between probiotics and host has a deep
impact in many ways. One is to stimulate the immune system
by promoting Th1 and T regulatory (Treg) immunity, and
by decreasing Th2 activity in allergic subjects (Elson and
Cong 2002). In this regard, Bacillus clausii is a probiotic
capable of modulating the immune response (Ciprandi et al
2005a, 2005b). Specifically, it has been demonstrated that
B. clausii stimulates Th1 and Treg immunity, promoting IL-
12, IFN-γ, IL-10, and transforming growth factor-beta (TGF-
β) synthesis, and down-regulates Th2 response, inhibiting
IL-4 production, in allergic children with RRI (Ciprandi et
al 2004).
Therefore, this pilot study was performed to assess the
efficacy and the safety of B. clausii in the prevention of
RRI in children.
Methods
Probiotic
Bacillus clausii is an aerobic, spore-forming bacterium that
is able to survive transit through the acidic environment of
the stomach and colonize the intestine even in the presence
of antibiotics (Duc et al 2004). B. clausii is available for
oral use as a suspension of 2 billion spores per 5 mL.
Population and eligibility criteria
Eighty children (39 males and 41 females, mean age 4.3 ±
1.5 years) with RRI were enrolled in the study, among these
the atopics were 18 in the B. clausii group and 19 in the
other one. Inclusion criteria were: out-patients of both sexes,
aged 3–6 years, attending a nursery or primary school,
positive history for RRI in the last 12 months (≥6 episodes),
good general conditions, and written informed consent of
at least one parent. Exclusion criteria were: primary or
acquired immunodeficiency, hypersensitivity to the study
treatment, previous (last 3 months) or concomitant
administration of drugs capable of interfering with the study
(eg, immunomodulants, homeopathic therapy, or systemic
corticosteroids for at least 2 consecutive weeks), use of
antiallergic drugs (ie, topical corticosteroids,
antileukotrienes, cromones) during the study, history of
chronic disease, cancer, or congenital malformation of the
airways.
Study design
A randomized, single-blind, multi-centre, two arm parallel-
group protocol was designed. The study was approved by
the ethics committee – IRCCS San Matteo – Pavia.
Study medication
At the first visit, B. clausii was randomly prescribed to 40
children in a blinded manner so that investigators were
unaware which children were given the probiotic. One vial
of B. clausii was to be taken orally twice daily for 90 days.
As rescue medication for allergic children, an antihistamine
(desloratadine) was allowed for symtomatic use alone.
Safety
Safety and tolerability of the probiotic were evaluated on
the basis of the number and type of adverse events recorded
according to the principles of good clinical practice.
Study procedures
The children were examined at study entry and every month
for 3 months (treatment period). After the initial treatment
period there was a further 3 months of follow-up during
which the children were monitored monthly. The studyTherapeutics and Clinical Risk Management 2007:3(1) 15
Bacillus clausii in the prevention of recurrent respiratory infections
started in January 2004 and ended in July 2004. At each
visit, a history of infections occurring during the preceding
period was taken and a clinical examination was also
conducted. The investigators diagnosed RI on the basis of
the symptoms recorded by the parent in the study diary and
noted the duration of the episodes. The diagnosis of RI was
made when at least 2 symptoms or fever (axillary
temperature ≥38°C), in addition to one other symptom, were
present for at least 48 hours. The symptoms taken into
consideration for diagnostic purposes were: mucopurulent
rhinorrhea, stuffy or dripping nose or both, sore-throat,
cough (dry or productive), otalgia (earache), fever,
dyspnoea, and mucopurulent secretion. Allergy was
diagnosed on the basis of positivity to skin prick test
according to validated criteria (Ciprandi et al 2004).
Eighteen allergic children were actively treated and nineteen
acted as controls.
Statistical analysis
The main descriptive statistics were calculated for each
variable: mean, median, and standard deviation for
quantitative variables. Also the 95% confidence limits were
calculated whenever relevant. The efficacy analysis was
carried out using the χ
2 test.
Results
A total of 80 subjects were enrolled in the study. Forty
children were treated with B. clausii and 40 children were
in the control group. They all completed the study.
Demographic and baseline variables were not significantly
different among the two groups.
Efficacy
Treatment period
Children treated with probiotic showed a significantly
reduced duration (mean 11.7 ± 4.8 days) of RI in comparison
with the control group (mean 14.37 ± 6.3) (p=0.037) as
reported in Figure 1. The number of RI was less in the
probiotic group (3.2 ± 0.8) compared with controls (3.9 ±
0.8). Regarding allergic children, the duration of RI was
shorter in the probiotic group (13.44 ± 4.6) than in the
nontreated controls (15.36 ± 7.4), as illustrated in Figure 2.
Follow-up period
Bacillus clausii-treated children had a shorter duration (6.6
± 3.1) of RI than controls (10.92 ± 5) (p=0.049). The number
of RI was less in actively treated children (1.95 ± 0.9) than
in controls (3 ± 1). Moreover, allergic treated children had
shorter durations of RI (7.72 ± 2.9) than allergic nontreated
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Figure 1 Duration of RI (expressed as days in treated and nontreated as children with RRI during the treatment period (white column) and the follow-up (grey
column).
Abbreviations: RI, respiratory infections; RRI, recurrent respiratory infections.Therapeutics and Clinical Risk Management 2007:3(1) 16
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(13.1 ± 5.3) (p=0.039). The use of symptomatic
antihistamine was very slight in both groups.
Safety
None of the children were withdrawn from the study because
of adverse events and very few mild adverse events occurred
(3 diarrhoea episodes). Indeed, such events were either
related to the underlying disease (RI) or not considered
treatment-related.
The tolerability profile exhibited in the B. clausii group
was similar to that of the control group. The proportion of
patients who experienced adverse events was similar in the
two groups both during the treatment phase and the follow-up.
Discussion
This preliminary study shows that B. clausii treatment is
significantly effective (p=0.037) in reducing the duration
of RI in children with recurrent disease. It is important to
note that this study provides the first evidence concerning
the capability of B. clausii in reducing the severity of
recurrent RI. Moreover, in probiotic-treated children, the
duration of RI episodes during the follow-up period was
also significantly shortened (p=0.049). Furthemore, it is well
known that allergic children experience more numerous and
more severe RI than normal subjects, and yet B. clausii was
also effective in preventing RI also in such atopic children
during follow-up.
Enterogermina 2 billions/5 ml is a treatment product for
oral use that contains a single active ingredient, namely
polyantibiotic-resistant spores of B. clausii. It is provided
in the form of a suspension containing 2 billion spores per
5 ml. The spores belong to 4 strains (O/C, T, N/R, and SIN)
that are resistant to different classes of antibiotics. B. clausii
is an aerobic, spore-forming bacterium that is able to inhibit
the growth of pathogens in the gastrointestinal tract via three
distinct mechanisms: colonization of free ecological niches,
which are no longer available for the growth of other micro-
organisms; competition for epithelial cell adhesion, which
is particularly relevant for spores in the initial or intermediate
germination phase; production of antibiotics and/or enzymes
secreted into the intestinal environment, especially peptide
antibiotics, which are mainly active on Gram-positive
bacteria, but also enzymes that exhibit lytic activity against
Pseudomonas aeruginosa. The B. clausii of Enterogermina
has proven to be highly resistant to gastric acidity and most
antibiotics, with the exception of sulfonamides and
Figure 2 Duration of RI (expressed as days) in treated and nontreated allergic children with RRI during the treatment period (white column) and the follow-up (grey
column).
Abbreviations: RI, respiratory infections; RRI, recurrent respiratory infections.
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trimethoprim, a few aminoglycosides and nitrofurans,
combinations of penicillins with beta-lactamase inhibitors
and vancomycin.
The possible mechanism of action may be due to its
modulatory activity on the immune response as previously
reported in a study in allergic children with RRI (Ciprandi
et al 2004). In fact, RRI may be linked to a “relative”
immaturity of the immune system that is typically Th2
polarized in first and second years of infancy (Ciprandi et
al 2004). B. clausii could redirect the immune response
towards a more physiologic Th1 oriented polarization that
can adequately fight infections mainly through IFN-γ. This
phenomenon is associated with on the stimulation of Treg
cells releasing cytokines necessary for stimulating the
Th1 response. Moreover, previous studies have
demonstrated that B. clausii stimulates the production of
IgA (Fiorini et al 1985). IgA synthesis is under the strict
control of TGF-β that is produced by Treg cells (Sporn
and Roberts 1992). Therefore, different immunological
mechanisms of action may explain the preventive activity
exerted by B. clausii in reducing the duration of RI, even
though immunological parameters were not investigated
in this study.
In conclusion, this study provides the first preliminary
evidence that B. clausii may exert a significant and persistent
preventive activity on RI in children and is safe and well
tolerated.
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